Novo Nordisk Cuts U.S. Wegovy and Ozempic Prices by 50% as Zepbound Surges
Novo Nordisk will slash U.S. list prices for Wegovy and Ozempic by up to 50% from March 1 to defend its GLP-1 market share. The company also warns Wegovy volumes will decline as Eli Lilly’s weight-loss drug Zepbound gains market share, intensifying competition.
1. Price Reduction Announcement
Novo Nordisk will slash U.S. list prices for its GLP-1 therapies Wegovy and Ozempic by up to 50% from March 1, aimed at defending share against rising competition.
2. Sales Outlook
The company warns that Wegovy volumes will decline as Eli Lilly's weight-loss drug Zepbound gains market share, signaling a shift in patient preference and prescribing patterns.
3. Competitive Implications
Eli Lilly stands to benefit from the pricing actions by capturing patients seeking effective alternatives, with Zepbound and Mounjaro positioned for accelerated uptake in the U.S. market.
4. Financial Impact
Novo Nordisk's U.S. revenue and margin profile may come under pressure from the cuts, while Lilly could see improved scale-driven profitability and stronger cash flow.